All Posts

COVID-19: VWF/ADAMTS13 Balance

Thanks to Brandon Michael Henry MD, Cincinnati Children’s Hospital Medical Center for drawing attention to his award-winning review, co-authored with Drs. Emmanuel Favaloro and Giuseppe Lippi, which details the relationship between von Willebrand factor and ADAMTS13 and applies the VWF/ADAMTS13 activity ratio to the thrombotic progression of the SARS-CoV2 infection. The authors review 67 primary […]

Arterial Thrombosis

February 2022 Cheat Sheet

Our February 2022 Cheat Sheet is attached. Please contact George at [email protected] if you’d like a push copy to arrive in your mailbox.

February, 2022 Quick Question: Platelet Aggs

Our February 2022 Quick Question asks, What single agonist is your first choice to measure platelet response to aspirin? The typical aggregation profile includes several agonists, however it may be that one is more sensitive to aspirin’s antiplatelet effect than the others. As always, please add your comments below.

Antiplatelet Therapy

January 2022 Quick Question: Case Study

We had 58 responses to our January 2022 Quick Question. The stem asked, “A patient experiences soft tissue bleeding and poor wound healing. The PT, PTT, and TT are normal. What follow-up profile do you recommend? Factors VIII, IX, & XI assays: 10% [6] PAI-1 & D-dimer assays: 0 Thrombosis risk profile: 2% [1] Platelet […]

Bleeding Disorders

Chromogenic Vs. Clot-based Gene Transfer FVIII Assays

This article in Blood illustrates the disparity between chromogenic and clot-based factor VIII assays when measuring factor VIII activity produced by hemophilic recipients of gene transfer factor VIII: Rosen S, Tiefenbacker S, Robinson M, et al. Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy. Blood 2020;136:2524–34. Thanks to Dean Willett, […]

Bleeding Disorders

Biomarin Factor VIII Gene Transfer Results

Click here to see Biomarin’s 1-9-22 announcement of their 134-participant factor VIII gene transfer trial, valoctocogene roxaparvovec. Thanks to Dean Willett, Precision BioLogic Inc. for alerting us to this encouraging development.

Bleeding Disorders

THSNA Postponed to 8-25-22

Thanks to Elaine Benoit, Precision BioLogic inc., for alerting us to this change in the THSNA schedule: THSNA 2022 Summit Update Greetings Colleagues! The combination of patient surges and staffing shortages has created an unprecedented strain on the healthcare system. In light of this, the THSNA Board of Directors has decided to postpone THSNA 2022 until […]

The Fiix-PT Assay; Improves on PT-INR?

I [Geo] received a communication from Dr. Pall Onundarson, Hematology Laboratory and Thrombosis and Hemostasis Service, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, about the Fiix-PT assay designed to monitor vitamin K antagonist [warfarin, Coumadin] therapy unaffected by reductions in FVII and FIX which the authors claim to play little role in clinical anticoagulation. […]

Anticoagulant Therapy

January 2022 Cheat Sheet

Click here for your January 2022 Fritsma Factor Cheat Sheet. You will also receive the Sheet via email if you are on our Cheat Sheet distribution list. If you’d like to be included, please contact George at [email protected].

January 2022 Quick Question: Case Study

Our January 2022 case study states, “A patient experiences soft tissue bleeding and poor wound healing. The PT, PTT, and TT are normal. What follow-up profile do you recommend?” Please select your answer from the column on the right and add your comments below.

Quick Question Archive

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question